![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Project Team for Pharmacogenetics (S.K., Y.S., M.N., K.Mae., N.M., S.O., J.S.) and Divisions of Biochemistry and Immunochemistry (Y.S., K.Mae., J.S.), Microbiology (Y.K.), Xenobiotic Metabolism and Disposition (T.F.), and Pharmacology (S.O.), National Institute of Health Sciences, Tokyo, Japan; and Department of Allergy and Immunology (T.N., K.Mat., H.S.), National Research Institute for Child Health and Development, National Center for Child Health and Development, Tokyo, Japan
Received May 7, 2003; accepted June 23, 2003.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
B (NF-B). To identify genetic polymorphisms affecting glucocorticoid responses, the GR gene was sequenced, and two novel single nucleotide alterations, 1510A>T (T504S) and 1952C>T (S651F), were identified in addition to an adenine base insertion at nucleotide 2314 (2314insA). mRNA expression levels of T504S and S651F were comparable with that of the wild type (WT), whereas the mRNA level of 2314insA was reduced to 
36% of the WT level. Protein expression was reduced to 66% of WT levels in S651F and to 6% in 2314insA. No significant change was seen in the T504S variant levels. The instability of the 2314insA mRNA, S651F protein, and 2314insA protein was confirmed by time course experiments. The transcriptional activity of S651F and 2314insA was also reduced to approximately 63 and 2% of the WT levels, respectively, in the luciferase reporter assay. Moreover, the inhibitory effect of GR on NF-B transactivation was reduced to approximately 81 and 12% of the WT levels for S651F and 2314insA, respectively. These results indicated that the overall transcriptional activity and inhibitory effect on NF-B transactivation of S651F and 2314insA have partially reduced and almost abrogated, respectively, almost paralleling their reduced protein expression levels caused by mRNA and/or protein instabilities. Thus, these two variations were suggested to influence the response to glucocorticoid treatment.
(hGR) is encoded by nine exons, including exon 9 (Encio and Detera-Wadleigh, 1991
). GR
is an alternatively spliced form with exon 9 replacing exon 9 that was identified in glucocorticoid-resistant human multiple myeloma cells and functions as an hGR dominant negative type (Moalli et al., 1993). The 777-amino acid hGR has many functional domains, which include DNA binding (amino acid residues 421–486), ligand binding (528–720), homodimerization (456–777), Hsp90 binding (568–653), nuclear translocation (479–506 and 526–777), and transactivation domains (77–262, 404–491, and 526–556) (Savory et al., 1999; Vottero and Chrousos, 1999). In the cytosol, GRs are associated with heat-shock and other proteins (Pratt and Toft, 1997), and the binding of glucocorticoid leads to their nuclear translocation (Webster and Cidlowski, 1999).
Glucocorticoid treatments are effective in many inflammatory diseases and some types of cancers. As for anti-inflammatory effects, GR is thought to exert its pharmacological effects through the activation of transcription, such as activating the glucocorticoid-induced leucine zipper gene, and/or through suppression of nuclear factor-B (NF-B) and AP-1-induced transcription of genes, such as inflammatory cytokines (Reichardt et al., 1998; De Bosscher et al., 2000; Berrebi et al., 2003). However, a small number of patients do not respond to clinically relevant doses of glucocorticoids, a condition that is termed glucocorticoid resistance (Loke et al., 2002). Several familial mutations in the GR gene have been shown to be associated with corticosteroid resistance or hematological malignancies, but these mutations are relatively rare and thought not to be a common cause of resistance (DeRijk et al., 2002). Recently, single nucleotide polymorphisms in the GR gene have been identified, some of which are relatively frequent (Panarelli et al., 1998; Ruiz et al., 2001; DeRijk et al., 2002). For example, a BclI restriction fragment polymorphism and an N363S alteration have been reported to influence the regulation of the hypothalamic-pituitary-adrenal axis and to be associated with changes in metabolism and cardiovascular control (Panarelli et al., 1998; DeRijk et al., 2002). Moreover, it has been reported that the I559N GR variant has a transdominant effect on wild-type GR by inhibiting its nuclear translocation (Kino et al., 2002). Furthermore, the I747M GR variant causes autosomal dominant glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators (Vottero et al., 2002). However, little information on single nucleotide polymorphisms in the GR gene is available for the Asian population.
In this study, the coding regions of the GR gene were sequenced from 88 Japanese allergic subjects and 73 established cell lines from Japanese individuals. Two novel non-synonymous single nucleotide changes were found in addition to a previously reported adenine insertion, which induces a frameshift. Then, the effects of these nucleotide changes were assessed on the mRNA and protein expression levels, transcriptional activity, and inhibitory effect on NF-B transactivation.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The primers for the polymerase chain reaction (PCR) and sequencing of the coding regions were designed based on the nucleotide sequences from the National Center for Biotechnology Information database (M78506
[GenBank]
, M78507
[GenBank]
, U78508
[GenBank]
, and AC004782
[GenBank]
). All primers used in this study have been previously described (Nagano et al., 2002). PCR conditions and sequencing methods were as previously described (Koyano et al., 2002).
Plasmids and Transfection. pRShGR was obtained from the American Type Culture Collection (Manassas, VA), which contains the full-length coding region of human GR and the active Rous sarcoma virus promoter (Giguere et al., 1986). Three expression plasmids encoding the variant GRs (T504S, S651F, and 2314insA) were prepared with a QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) using the wild-type pRShGR plasmid as a template. The empty vector plasmid used as a control was prepared by removing the hGR cDNA from the pRShGR plasmid. The wild-type (WT) expression plasmid (pRShGR 0.1–0.5 µg) was first titrated with 0.6 µg of the mouse mammary tumor virus (MMTV) promoter-luciferase reporter construct (pHH-Luc, the reporter plasmid described under Luciferase Reporter Assay) using COS-7 cells (1.4 x 105 cells) for Western blot analysis and luciferase activity. These results indicated that protein expression levels and luciferase activities linearly increased depending on the amounts of the transfected plasmid (data not shown). Thus, 0.3 µg of the WT or variant expression plasmids per 1.4 x 105 cells was utilized for transfection. phRL-TK (Promega, Madison, WI) encoding Renilla (sea pansy) luciferase was used for cotransfection and normalization of transfection efficiency. To assess the efficiency of each transfection, the Renilla luciferase activity was measured from transfected cell lysates. All of the transfection efficiencies were consistent in Northern and Western blot analyses (92–103% of the WT hGR expression plasmid among all of the variant expression plasmids). The PathDetect NF-B cis-Reporting System (Stratagene) was used in the inhibition experiments for NF-B transcriptional activity by the GR variants. pFC-MEKK (Stratagene) expressing constitutive active MEKK (amino acid 360-672) was used as a positive control activating NF-B. pNF-B-luc (Stratagene) was a 5xNF-B binding element-driven firefly luciferase plasmid.
Cell Culture. COS-7, an African green monkey kidney cell line, was chosen for transfection of the GR expression plasmids since the endogenous GR levels are low (see Figs. 1 and 2). COS-7 cells were obtained from JCRB and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 U/ml penicillin and streptomycin under an atmosphere of 5% CO2 at 37°C. For dexamethasone treatment, cells were cultured in Dulbecco's modified Eagle's medium supplemented with fetal bovine serum (10%) that was pretreated with dextran-coated charcoal to remove endogenous glucocorticoids.
|
|
Northern Blot Analysis. COS-7 cells (1.6 x 106 cells) were cotransfected with 3.5 µg of expression plasmid for the wild-type or variant GRs and 0.5 µg of the phRL-TK plasmid using the PolyFect Transfection Reagent (Qiagen). The cells were harvested 48 h after transfection, and total RNA was extracted with the RNeasy kit (Qiagen). Because all of the transfection efficiencies were similar, as described above, an equal amount of total RNA (5 µg) from each RNA sample was subjected to electrophoresis, transferred to a nylon membrane (GeneScreen Plus; PerkinElmer Life Sciences, Boston, MA), and hybridized with 32P-labeled hGR or monkey glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe as previously described (Brown and Mackey, 1997). hGR cDNA was generated by digesting the pRShGR plasmid with KpnI and XhoI. Monkey GAPDH cDNA was prepared by reverse transcription-PCR using monkey GAPDH-specific primer pairs and COS-7 cell total RNA as a template. The hybridized signals were analyzed with a Bioimage Analyzer BAS-1500 (Fujifilm, Tokyo, Japan). The expression levels were quantified from three separate transfection experiments.
Western Blot Analysis. The cotransfected COS-7 cells (1.6 x 106 cells) were prepared as described above, and the cell pellets were boiled in a protein sample buffer. Because all of the transfection efficiencies were similar, as described above, an equal amount of total protein (20 µg) was separated on a 6% SDS-polyacrylamide gel (Tefuco Co., Tokyo, Japan) and transferred onto a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). The membrane was blocked with 5% skim milk and incubated with polyclonal rabbit anti-human GR antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and then with goat anti-rabbit IgG conjugated with horse-radish peroxidase (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK) for the secondary antibody. GR protein was visualized with the SuperSignal West Femto maximum sensitivity substrate (Pierce Chemical, Rockford, IL) according to the manufacturer's instructions. The signals were assessed by densitometric analysis. The expression levels were quantified from three separate transfection experiments.
Time Course Experiments of 2314insA mRNA and S651F and 2314insA Proteins. Time course experiments were performed essentially as previously described (Webster et al., 1997). For the measurement of mRNA levels, COS-7 cells were transfected with GR WT or the 2314insA expression plasmid as described above and 32 h later were treated with 1 µg/ml of actinomycin D for 1 h, followed by a 24-h incubation. Total RNA was prepared after 0, 3, 6, 12, and 24 h and analyzed by Northern blotting. Two independent transfection experiments were performed. For protein level measurements, COS-7 cells were transfected with the GR WT, S651F, or 2314insA expression plasmid and 42 h later were treated with 1 µM cycloheximide for 1 h, then incubated for an additional 48 h. Whole cell lysates were prepared after 0, 3, 6, 12, 24, and 48 h and subjected to Western blotting. The expression levels were quantified from three separate transfection experiments.
Immunocytochemistry. COS-7 cells (1.6 x 106 cells) were transfected with 4 µg of the expression plasmid for wild-type or variant GR and then cultured for 48 h. The cells were treated with vehicle or 100 nM dexamethasone for 90 min. Transfected COS-7 cells were washed twice with PBS, fixed with 3.7% formaldehyde in PBS for 15 min at room temperature, and then permeabilized with 0.5% Triton X-100 for 15 min. The fixed cells were blocked by incubation with PBS containing 10% goat serum and simultaneously treated with 100 ng/ml of DAPI (Santa Cruz Biotechnology, Inc.) for 30 min at room temperature and then washed with PBS containing 0.05% Tween 20. Next, the cells were incubated overnight at 4°C with rabbit polyclonal anti-GR antibody (Santa Cruz Biotechnology, Inc.) diluted in PBS containing 10% goat serum. They were washed five times with PBS containing 0.05% Tween 20 and incubated for 1 h at room temperature with anti-IgG (rabbit) conjugated with Alex 594 (Funakoshi Co., Tokyo, Japan) diluted in PBS containing 10% goat serum. Immunoreacted GR and the nuclei stained with DAPI were visualized by fluorescent microscopy.
Luciferase Reporter Assay. COS-7 cells (1.4 x 105 cells) were cotransfected with 0.3 µg of the wild-type GR expression plasmid pRShGR or the variant GR expression plasmid together with 0.6 µg of MMTV promoter-luciferase reporter construct pHH-Luc (American Type Culture Collection) (GenBank accession number AF093686
[GenBank]
) and 0.6 µg of phRL-TK plasmid as an internal control. Twenty-four hours after transfection, the cells were treated with vehicle (methanol) or various concentrations of dexamethasone (DEX), then cultured for an additional 24 h. The cells were washed with PBS, and the lysates were prepared using the PicaGene Dual Sea Pansy Luminescence kit (Nippon Gene Co., Ltd., Tokyo, Japan). Luciferase activity was then measured using a VICTOR2 Multilabel Counter (PerkinElmer Wallac, Turku, Finland). All transfection efficiencies were normalized according to the Renilla luciferase activity. Quantification was done from three independent transfection experiments.
Inhibition of NF-B Transcriptional Activity by the GR Variants. The Pathdetect NF-B cis-reporting system (Stratagene) was used in the assay for inhibition of NF-B transcriptional activity of the GR variants. COS-7 cells (2.8 x 104 cells) were cotransfected with 5 ng of 5xNF-B-luc reporter plasmid and 50 ng of phRL-TK, with or without 50 ng of either the WT or variant (T504S, S651F, or 2314insA) expression plasmids, and 5 ng of pFC-MEKK. Twenty-four hours after transfection, the cells were treated with 100 nM DEX for an additional 43 h. The cell lysates were prepared, and their luciferase activities were measured. All transfection efficiencies were normalized according to Renilla luciferase activity. Quantification was done from three independent transfection experiments.
Statistical Analysis. The results of the Northern blot analysis, Western blot analysis, and reporter assays were assessed for their statistical significance by one-way analysis of variance, followed by Fisher's PLSD method using StatView software (SAS Institute Inc., Cary, NC).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
), resulting in a substitution of six amino acid residues and an additional 20 residues at the end of the C terminus (LLFHQK to TSVSSKVTALIRMVALKKVELIAFIV). This insertion was detected as a heterozygote in cell line CCK-81 (Health Science Research Resources Bank accession number JCRB0208), which was derived from a Japanese patient with colon adenoma (Koura and Isaka, 1980; Sakurai et al., 1988) and is identical to the insertion that Jiang et al. (2001) found in 8 of 39 lupus nephritis patients. We also characterized the functional effect of this insertion, since its functional significance was unclear. Expression of the Variant GR mRNA in the Transfected COS-7 Cells. To determine expression levels of the variant GR mRNAs, Northern blot analysis was performed using total RNA from COS-7 cells transfected with the wild-type or variant expression plasmids (n = 3) (Fig. 1). From Northern blot analysis, the GR mRNA expression levels of the T504S, S651F, and 2314insA variants were estimated at 113.7 ± 12.2, 85.9 ± 5.5, and 35.6 ± 1.0 (p < 0.005), respectively, when the expression level of the WT GR was defined as 100. Thus, the mRNA expression levels of T504S GR and S651F GR were similar to that of the WT, but the 2314insA GR expression was significantly reduced.
Expression Levels of Variant GR Proteins in Total Cell Lysates. To quantify the expression levels of the variant GR proteins, we performed Western blot analysis of total cell lysates from the transfected COS-7 cells using an anti-GR antibody (n = 3). By densitometric quantification, the protein expression levels of the T504S, S651F, and 2314insA GR variants were estimated at 90.2 ± 15.1, 65.6 ± 4.3 (p < 0.05), and 6.3 ± 1.7 (p < 0.001), respectively, when the WT expression level was defined as 100. No significant difference in the expressed protein levels was found between the WT and T504S (Fig. 2). However, S651F expression was significantly reduced, and the 2314insA protein levels were drastically reduced (Fig. 2). Considering the results of the Northern blot analysis, it is likely that the reductions seen in the S651F and 2314insA protein levels were caused by protein instability or ineffective translation in COS-7 cells in addition to mRNA instability for 2314insA.
GR Variant mRNA and Protein Time Course Experiments. Because the GR variants showed reduced expression of mRNA (2314insA) and protein (S651F and 2314insA) compared with the WT, as shown in Figs. 1 and 2, time course experiments were performed for the 2314insA mRNA and the S651F and 2314insA proteins. For mRNA, the amount of 2314insA mRNA (t1/2 = 9 h) decreased faster than that of WT mRNA (t1/2 = 20 h) in COS-7 cells in the presence of actinomycin D (n = 2) (Fig. 3A). For protein, half-lives of the WT, S651F, and 2314insA proteins in the presence of cycloheximide were approximately 12, 9, and 6 h, respectively (n = 3) (Fig. 3B). These results suggested that instabilities of the 2314insA mRNA and protein and of the S651F protein cause their reduced protein levels.
|
Subcellular Localization of the Variant GR. GR exists in the cytoplasm in a glucocorticoid-free form (Sanchez et al., 1986; Gustafsson et al., 1989). To investigate the subcellular localization of each variant GR, immunostaining of COS-7 cells transfected with the WT or variant GR plasmids was done (n = 3) (Fig. 4). When WT-transfected cells were not treated with DEX, the expressed receptors were cytoplasmic. In contrast, when cells were treated with 100 nM DEX, most of the wild-type GR proteins were localized in the nucleus. The localization patterns of T504S and S651F variant proteins were similar to that of the WT (Fig. 4). In contrast, the 2314insA variant protein was barely detectable in the cytoplasm (data not shown), which was consistent with the Western blot results. Long exposure showed that the 2314insA protein was distributed in the cytoplasm even if the cells were treated with 100 nM DEX (Fig. 4). Thus, this variant protein is suggested to also lack glucocorticoid-dependent nuclear translocation ability.
|
Transcriptional Activity of the Variant GRs. GRs induce expression of a variety of genes. GRs are thought to also exert their anti-inflammatory effects partly via activation of transcription of the genes, such as recently identified glucocorticoid-induced leucine zipper genes, the proteins of which interfere with NF-B and AP-1 function (Mittelstadt and Ashwell, 2001; Berrebi et al., 2003). To investigate the transcriptional activity of the variant GRs, COS-7 cells were transfected with the WT or variant GR expression plasmid together with a plasmid containing the MMTV promoterluciferase reporter construct (pHH-Luc). The MMTV promoter has been extensively used as a model system to study the mechanisms of glucocorticoid-mediated gene regulation (Medh and Schmidt, 1997) and contains a well characterized glucocorticoid-responsive element that mediates transcriptional activation. The results of the reporter gene experiments are shown in Fig. 5 (n = 3). Transfection of COS-7 cells with the empty vector plasmid alone induced no luciferase activity, even with dexamethasone treatment. When the WT was transfected, luciferase activity increased in a dose-dependent manner with dexamethasone. Similarly, the T504S variant showed an increase in luciferase activity comparable with that of the WT. In contrast, the S651F variant treated with 100 nM dexamethasone showed a significant decrease to approximately 62.9 ± 13.3% (p < 0.001) of the WT levels. Furthermore, the 2314insA variant GR induced little or no luciferase activity. The transcriptional activities of the variant GRs correlated well with their protein expression levels (Fig. 2).
|
Inhibition of NF-B Activation by the GR Variants. It has been generally thought that the GR suppresses inflammation by transcription inhibition of proinflammatory genes induced by other nuclear factors, such as NF-B (Reichardt et al., 1998; De Bosscher et al., 2000). Thus, we examined the inhibitory ability of the GR variants on NF-B transactivation (n = 3) (Fig. 6). NF-B transactivation was assayed using the 5xNF-B enhancer-containing luciferase plasmid and the MEKK expression plasmid. This assay system used endogenous NF-B in COS-7 cells (Reinhard et al., 1997). The 5xNF-B-driven luciferase activity increased more than 200-fold with cotransfection of the constitutively active MEKK expression plasmid as compared with that of the cotransfected vehicle alone (data not shown). By cotransfecting the WT expression plasmid, the NF-B-dependent 5xNF-B-driven luciferase activity was reduced to 17.9 ± 3.8% (p < 0.001) compared with cotransfection of the MEKK expression plasmid alone (data not shown). When inhibitory effects of WT were defined as 100%, the NF-B-dependent luciferase activities were inhibited to 100 ± 5.2%, 81 ± 9.4% (p < 0.005), and 12 ± 2.9% (p < 0.001) when cotransfected with T504S, S651F, and 2314insA expression plasmids, respectively (Fig. 6). These results indicated that the inhibitory effect of the GR variants on the NF-B transactivation almost correlates with their protein expression levels, similar to their transcriptional activation properties.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
To date, it has been shown that NF-B and GR have opposing actions in the modulation of the immune/inflammatory responses (McKay and Cidlowski, 2000). NF-B induces the expression of proinflammatory genes, whereas GR suppresses immune function, in part, by reducing the expression of the same genes. The molecular mechanism of GR function is still controversial, but its direct binding to the NF-B p65 subunit is thought to be involved in the subsequent suppression of NF-B-mediated transactivation (Reichardt et al., 1998; De Bosscher et al., 2000; Nissen and Yamamoto, 2000). Therefore, we also examined an inhibitory effect of the GR variants on NF-B transcriptional activation (Fig. 6). In addition, GR also transactivates several genes including the recently identified glucocorticoid-induced leucine zipper gene, the protein of which interferes with the function of NF-B and AP-1. Thus, glucocorticoid-induced transactivation is also suggested to be involved in its anti-inflammatory effects (Mittelstadt and Ashwell, 2001; Berrebi et al., 2003).
Recently, Jiang et al. (2001) reported the same adenine insertion polymorphism (insertion of A at 2439) in 8 of 39 lupus nephritis patients and claimed that the lupus nephritis patients had a lower glucocorticoid-binding capacity in peripheral blood mononuclear cells. Thus, although we detected this insertional variation in an established cell line, this is a true polymorphism, not a mutation formed during tumorigenesis. Because they examined the ligand-binding capacity for mixed samples of the variant and wild-type GRs, the functional changes caused by the insertion were unclear. Thus, our study determined, for the first time, the functional changes caused by this insertion.
For the 2314insA variant, the mRNA level, protein level, transcriptional activity, and inhibitory effects on NF-B were reduced to approximately 36, 6, 2, and 12% of the WT, respectively (Figs. 1, 2, 5, and 6). This indicated that the insertion influences both mRNA and protein expression, and its reduced transcriptional activity and inhibitory effects on NF-B almost correlated with its protein level. Because the variant expression plasmids had the same Rous sarcoma virus promoter region, it was likely that the reduced mRNA levels in the 2314insA variant were caused by mRNA instability in the COS-7 cells. This was confirmed by the time course experiment (Fig. 3A), which showed that the expression of the 2314insA mRNA decreased faster than that of the GR WT mRNA (Fig. 3A). Nonsense-mediated mRNA decay has been reported in many genes to destroy mRNA species that contain premature termination codons (Byers, 2002). Our case is different from the nonsense-mediated mRNA decay, since the 2314insA frameshift variant creates a stop codon 52 base pairs downstream from the normal one. However, Simpson and Stoltzfus (1994) have reported a v-src mutant mRNA, which causes a frameshift, resulting in the formation of a novel termination codon 13 base pairs downstream from the normal termination site of the src polypeptide. In this case, the expression level of the v-src mutant mRNA was reduced by approximately 40 to 50% of that of the wild type. It is possible that the mechanism of the reduced mRNA expression of the 2314insA variant is similar to the reduced expression of the v-src mutant mRNA. Since the half-life of the 2314insA protein was also reduced as compared with the WT (6 versus 12 h) (Fig. 3B), a significantly lower expression of the 2314insA protein was caused by both its mRNA and protein instabilities. This variant protein also suggested that it lacked glucocorticoid-dependent nuclear translocation ability (Fig. 4). Furthermore, the 2314insA variant lacks the functional activation function-2 domain, which is similar to hGR. Therefore, we have examined whether the 2314insA variant acts as a dominant negative type, like GR. COS-7 cells were transfected with the pHH-Luc reporter plasmid and equal amounts of 2314insA variant and/or WT expression plasmids and cultured in the presence of 100 nM dexamethasone. The luciferase activity of the COS-7 cells coexpressing 2314insA and WT was almost equal to that expressing WT alone, suggesting that 2314insA did not act as a dominant negative type against the WT GR (data not shown). Similar results were obtained for the inhibition of NF-B-mediated transactivation by GR (data not shown).
The S651F variant was found in an atopic dermatitis patient with a relatively poor response to glucocorticoid drugs. The protein level, transcriptional activity, and inhibitory effect on NF-B of S651F were reduced to approximately 66, 63, and 81%, respectively, compared with the wild type, without any changes in mRNA levels (Figs. 2, 5, and 6). This suggested that the reduction in the protein levels was attributed to protein instability or translational inefficiency. Then, the S651F protein half-life in COS-7 cells was determined. Time course experiments showed that the half-lives of WT and S651F were about 12 and 9h, respectively (Fig. 3B). Because the S651F mRNA was stable, similar to the WT mRNA (Fig. 1), reduced expression of the S651F protein was due only to its protein instability. Residue 651 is located in the Hsp90-binding domain. It is possible that the replacement of Ser-651 with phenylalanine affects the Hsp90 binding to the variant GR, since Hsp90 stabilizes the GR protein. The S651F variant was able to translocate to the nucleus in response to dexamethasone (Fig. 4).
Although Thr-504 is located in the nuclear translocation domain, the T504S protein translocates into the nucleus in response to dexamethasone (Fig. 4). This T504S variation was found in an atopic dermatitis patient who had a good response to glucocorticoid drugs. The T504S variant showed similar levels of mRNA, protein, transcriptional activity, and inhibitory effect on the NF-B transactivation compared with those of the wild type.
The results in this study demonstrated that the S651F and 2314insA variants have partially reduced and almost abrogated activities for transcription and NF-B inhibition, respectively, almost paralleling their reduced protein expression levels. Thus, these two variations may influence the response to glucocorticoid treatment.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: GR, glucocorticoid receptor; NF-B, nuclear factor-B; Hsp90, heat-shock protein 90; AP-1, activator protein-1; PCR, polymerase chain reaction; MMTV, mouse mammary tumor virus; DEX, dexamethasone; WT, wild-type; JCRB, Japanese Collection of Research Bioresources; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate-buffered saline; DAPI, 4,6-diamidino-2-phenylindole; MEKK, mitogen-activated protein kinase kinase kinase; PLSD, protected least significant difference.
Address correspondence to: Satoru Koyano, Project Team for Pharmacogenetics, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. E-mail: skoyano{at}nihs.go.jp
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet-Delbos L, Maillot MC, Portier A, Couderc J, Galanaud P, et al. (2003) Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 101: 729–738.
Brown T and Mackey K (1997) Analysis of RNA by Northern and slot blot hybridization, in Current Protocols in Molecular Biology (Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K eds), John Wiley & Sons, Inc., New York.
Byers PH (2002) Killing the messenger: new insights into nonsense-mediated mRNA decay. J Clin Invest 109: 3–6.[CrossRef][Medline]
De Bosscher K, Vanden Berghe W, and Haegeman G (2000) Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109: 16–22.[CrossRef][Medline]
DeRijk RH, Schaaf M, and de Kloet ER (2002) Glucocorticoid receptor variants: clinical implications. J Steroid Biochem Mol Biol 81: 103–122.[CrossRef][Medline]
Encio IJ and Detera-Wadleigh SD (1991) The genomic structure of the human glucocorticoid receptor. J Biol Chem 266: 7182–7188.
Giguere V, Hollenberg SM, Rosenfeld MG, and Evans RM (1986) Functional domains of the human glucocorticoid receptor. Cell 46: 645–652.[CrossRef][Medline]
Gustafsson JA, Wikstrom AC, and Denis M (1989) The non-activated glucocorticoid receptor: structure and activation. J Steroid Biochem 34: 53–62.[Medline]
Jiang T, Liu S, Tan M, Huang F, Sun Y, Dong X, Guan W, Huang L, and Zhou F (2001) The phase-shift mutation in the glucocorticoid receptor gene: potential etiologic significance of neuroendocrine mechanisms in lupus nephritis. Clin Chim Acta 313: 113–117.[CrossRef][Medline]
Kino T, Stauber RH, Resau JH, Pavlakis GN, and Chrousos GP (2002) Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab 86: 5600–5608.
Koura M and Isaka H (1980) Establishment of a human colon adenocarcinoma cell line producing carcinoembryonic antigen. Jpn J Cancer Clin 71: 313–318.
Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Nakajima T, et al. (2002) Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet 17: 561–565.
Loke TK, Sousa AR, Corrigan CJ, and Lee TH (2002) Glucocorticoid-resistant asthma. Curr Allergy Asthma Rep 2: 144–150.[Medline]
McKay LI and Cidlowski JA (2000) CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 14: 1222–1234.
Medh RD and Schmidt TJ (1997) Trans-retinoic acid and glucocorticoids synergistically induce transcription from the mouse mammary tumor virus promoter in human embryonic kidney cells. J Steroid Biochem Mol Biol 62: 129–142.[CrossRef][Medline]
Mittelstadt PR and Ashwell JD (2001) Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem 276: 29603–29610.
Moalli PA, Pillay S, Krett NL, and Rosen ST (1993) Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 53: 3877–3879.
Nagano M, Nakamura T, Niimi S, Fujino T, Nishimura T, Murayama N, Ishida S, Ozawa S, Saito Y, and Sawada J (2002) Substitution of arginine for cysteine 643 of the glucocorticoid receptor reduces its steroid-binding affinity and transcriptional activity. Cancer Lett 181: 109–114.[Medline]
Nissen RM and Yamamoto KR (2000) The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14: 2314–2329.
Panarelli M, Holloway CD, Fraser R, Connell JM, Ingram MC, Anderson NH, and Kenyon CJ (1998) Glucocorticoid receptor polymorphism, skin vasoconstriction and other metabolic intermediate phenotypes in normal human subjects. J Clin Endocrinol Metab 83: 1846–1852.
Pratt WB and Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306–360.
Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531–541.[CrossRef][Medline]
Reinhard C, Shamoon B, Shyamala V, and Williams LT (1997) Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 16: 1080–1092.[CrossRef][Medline]
Ruiz M, Lind U, Gafvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, Holtmann M, Stierna P, Wikstrom AC, and Werner S (2001) Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol 55: 363–371.[CrossRef][Medline]
Sakurai Y, Hirohashi S, Shimosato Y, Kodaira S, and Abe O (1988) Selection of a monoclonal antibody reactive with a high-molecular-weight glycoprotein circulating in the body fluid of gastrointestinal cancer patients. Cancer Res 48: 4053–4058.
Sanchez ER, Housley PR, and Pratt WB (1986) The molybdate-stabilized glucocorticoid binding complex of L-cells contains a 98-100 kdalton steroid binding phosphoprotein and a 90 kdalton nonsteroid-binding phosphoprotein that is part of the murine heat-shock complex. J Steroid Biochem 24: 9–18.[CrossRef][Medline]
Savory JG, Hsu B, Laquian IR, Giffin W, Reich T, Hache RJ, and Lefebvre YA (1999) Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 19: 1025–1037.
Simpson SB and Stoltzfus CM (1994) Frameshift mutations in the v-src gene of avian sarcoma virus act in cis to specifically reduce v-src mRNA levels. Mol Cell Biol 14: 1835–1844.
Vottero A and Chrousos GP (1999) Glucocorticoid receptor beta: view I. Trends Endocrinol Metab 10: 333–338.[CrossRef][Medline]
Vottero A, Kino T, Combe H, Lecomte P, and Chrousos GP (2002) A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab 87: 2658–2667.
Webster JC and Cidlowski JA (1999) Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol Metab 10: 396–402.[CrossRef][Medline]
Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, and Cidlowski JA (1997) Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 272: 9287–9293.
This article has been cited by other articles:
|
|
 |
|
  S. Koyano, Y. Saito, H. Fukushima-Uesaka, S. Ishida, S. Ozawa, N. Kamatani, H. Minami, A. Ohtsu, T. Hamaguchi, K. Shirao, et al. FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION Drug Metab. Dispos., August 1, 2005; 33(8): 1254 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koyano, K. Kurose, Y. Saito, S. Ozawa, R. Hasegawa, K. Komamura, K. Ueno, S. Kamakura, M. Kitakaze, T. Nakajima, et al. FUNCTIONAL CHARACTERIZATION OF FOUR NATURALLY OCCURRING VARIANTS OF HUMAN PREGNANE X RECEPTOR (PXR): ONE VARIANT CAUSES DRAMATIC LOSS OF BOTH DNA BINDING ACTIVITY AND THE TRANSACTIVATION OF THE CYP3A4 PROMOTER/ENHANCER REGION Drug Metab. Dispos., January 1, 2004; 32(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
